Swedish Orphan Biovitrum AB

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

71.44%

Market Cap

6.34 Bil.

P/E Ratio

240.65

Dividend Yield

0.00 %

Earnings per Share

0.13 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE41.88 G0 Units
PRICE DETERMINATION TIME07/21/2026 / 06:03:26 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW42.1641.64
PREV. DAY'S PRICE41.42 (07/20)
CHANGE DAY BEFORE
+0.46
1.11 %
52 WEEK HIGH / LOW43.76 (07/03)23.3 (08/01)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
0.650.990.131.692.06
DIVIDENDS PER SHARE
0.000.000.000.000.00
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
35.7628.06240.6524.7020.34
PRICE - BOOK RATIO
2.682.713.05--
PRICE - SALES RATIO
3.934.214.10--
PRICE - CASH FLOW RATIO
19.4714.8513.51--
Further Key Figures

Master Data

WKN
A0LA5K
ISIN
SE0000872095
SYMBOL
B6E
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
SWEDISH ORPHAN BIOVIT.SK1
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
Swedish Krona
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
339.76 Mil.
MARKET CAPITALISATION
6.34 Bil.

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-0.10 %
3.65 %
6.86 %
37.43 %
71.44 %
147.94 %
178.24 %
35.36 %
HIGH43.1643.7643.7643.7643.7643.7643.7643.76
LOW40.4039.8236.3030.2023.3016.1514.7330.04

Dividende

pro Aktie
SWEDISH ORPHAN BIOVIT.SK1 does not deliver dividend information

Company profile

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The Immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Stockholm, Sweden.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.